1. Genpact : Launches an Artificial Intelligence (AI)-Based Solution to Usher in a New Era of Drug Safety Automation

    NEW YORK, June 12, 2017 /PRNewswire/ -- Genpact (NYSE: G), a global professional services firm focused on delivering digital transformation for clients, is investing in leading digital technologies that are transforming industries. Genpact's PVAI will be the life sciences industry's first fully-integrated, end-to-end adverse event (AE) processing solution, leveraging intelligent automation to not only dramatically reduce the effort of processing adverse events, but also to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible. As life sciences companies face escalating AE volumes for their products and increasing pressure to improve quality and compliance while ...

    Read Full Article

    Login to comment.

  1. Categories

    1. Default:

      Discourse, Entailment, Machine Translation, NER, Parsing, Segmentation, Semantic, Sentiment, Summarization, WSD

    1. The November Research Group team is very excited to be part of the Genpact PVAI team and combining our deep domain expertise and our PV solutions with their AE data extraction engine, analytics, and innovative AI approach to provide a truly game-changing PV solution.
  3. Topics Mentioned